Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception

Abstract

Background

Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management.

Methods

Linear mixed models were fitted to study changes in VL and potential associated factors including HAART type or duration and immune status among 127 women receiving HAART at conception with detectable VL enrolled in the prospective European Collaborative Study.

Results

Median duration of HAART at conception was 10 months. A total of 78 (61%) women conceived while on protease inhibitor (PI)-based HAART. Overall, 72 (57%) women remained on the same HAART regimen throughout pregnancy, 24 (19%) switched regimens and 31 (24%) interrupted HAART during early pregnancy. The intention-to-treat model indicated constant VL up to 10 gestational weeks; thereafter, levels decreased significantly, by 0.06 log₁₀ copies/ml weekly until delivery. At baseline, immune status was significantly associated with HIV RNA levels. Excluding those with treatment interruption, there was no significant difference in VL slope between women who did and did not modify their HAART regimens (P=0.14); women conceiving on non-nucleoside reverse transcriptase inhibitor-based HAART had consistently lower VL throughout pregnancy than those on PI-based HAART (P=0.02). Most (64/103, 62%) women had detectable VL within 4 weeks of delivery (median 2.40 log₁₀ copies/ml). The overall mother-to-child transmission rate was 1.72% (95% confidence interval 0.21–6.1).

Conclusions

Practices regarding management of women conceiving on HAART with detectable VL vary in Western Europe. The existence of this group of pregnant women highlights the need for improved monitoring of and support for treated women before they become pregnant, as well as during pregnancy.

References

Thorne

, Newell

M.L.

Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues.

Med Wieku Rozwoj 2003; 7: 425–436.

Egger

, May

, Chene

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Lancet 2002; 360: 119–129.

Sterne

J.A.

, Hernan

M.A.

, Ledergerber

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.

Lancet 2005; 366: 378–384.

European Collaborative Study.

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.

Clin Infect Dis 2005; 40: 458–465.

Jasseron

, Mandelbrot

, Tubiana

Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women?

AIDS 2008; 22: 1503–1511.

Townsend

C.L.

, Cortina-Borja

, Peckham

C.S.

, de Ruiter

, Lyall

, Tookey

P.A.

Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006.

AIDS 2008; 22: 973–981.

Palella

F.J.

Jr. , Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

N Engl J Med 1998; 338: 853–860.

Heard

, Sitta

, Lert

Reproductive choice in men and women living with HIV: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA Study).

AIDS 2007; 21 Suppl 1: S77–S82.

European Collaborative Study. Increasing likelihood of further live births in HIV-infected women in recent years. BJOG 2005; 112: 881–888.

10.

Floridia

, Tamburrini

, Ravizza

Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs.

Antivir Ther 2006; 11: 941–946.

11.

Garcia

P.M.

, Kalish

L.A.

, Pitt

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

N Engl J Med 1999; 341: 394–402.

12.

US Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. (Updated 8 July 2008. Accessed 28 April 2009.) Available from http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf.

13.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. (Updated 3 November 2008. Accessed 28 April 2009.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.

14.

Gazzard

B.G.

; BHIVA Treatment Guidelines Writing Group. BHIVA guidelines for the treatment of HIV-1 infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563–608.

15.

European Collaborative Study.

Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.

Clin Infect Dis 2007; 44: 1647–1656.

16.

European Collaborative Study.

The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West.

AIDS 2006; 20: 1419–1427.

17.

Thiebaut

, Jacqmin-Gadda

Mixed models for longitudinal left-censored repeated measures.

Comput Methods Programs Biomed 2004; 74: 255–260.

18.

Hughes

J.P.

Mixed effects models with censored data with application to HIV RNA levels.

Biometrics 1999; 55: 625–629.

19.

European Collaborative Study.

Levels and patterns of HIV RNA viral load in untreated pregnant women.

Int J Infect Dis 2009; 13: 266–273.

20.

Phillips

A.N.

, Staszewski

, Weber

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

JAMA 2001; 286: 2560–2567.

21.

de Ruiter

, Mercey

, Anderson

British HIV Association. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008.

HIV Med 2008; 9: 452–502.

22.

Thorne

, Newell

M.L.

Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?

Drug Saf 2007; 30: 203–213.

23.

Fiore

, Heard

, Thorne

Reproductive experience of HIV-infected women living in Europe.

Hum Reprod 2008; 23: 2140–2144.

24.

Coll

, Lopez

, Hernandez

Fertility choices and management for HIV-positive women.

Curr Opin HIV AIDS 2008; 3: 186–192.

25.

Massad

L.S.

, Evans

C.T.

, Wilson

T.E.

Contraceptive use among U.S. women with HIV.

J Womens Health (Larchmt) 2007; 16: 657–666.

26.

Koenig

L.J.

, Espinoza

, Hodge

, Ruffo

Young, seropositive, and pregnant: epidemiologic and psychosocial perspectives on pregnant adolescents with human immunodeficiency virus infection.

Am J Obstet Gynecol 2007; 197: S123–S131.

27.

Bardeguez

A.D.

, Lindsey

J.C.

, Shannon

Adherence to antiretrovirals among US women during and after pregnancy.

J Acquir Immune Defic Syndr 2008; 48: 408–417.

28.

Mellins

C.A.

, Chu

, Malee

Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.

AIDS Care 2008; 20: 958–968.

29.

Vaz

M.J.

, Barros

S.M.

, Palacios

HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women.

Int J STD AIDS 2007; 18: 28–32.

30.

Zorrilla

C.D.

, Santiago

L.E.

, Knubson

Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV.

Cell Mol Biol 2003; 49: 1187–1192.

31.

Hart

, Curtis

, Wilkins

, Johnson

National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients.

HIV Med 2007; 8: 186–191.

32.

Paterson

D.L.

, Swindells

, Mohr

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Ann Intern Med 2000; 133: 21–30.

33.

Maggiolo

, Ravasio

, Ripamonti

Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.

Clin Infect Dis 2005; 40: 158–163.

34.

Bangsberg

D.R.

Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression.

Clin Infect Dis 2006; 43: 939–941.

35.

Mirochnick

, Capparelli

Pharmacokinetics of antiretrovirals in pregnant women.

Clin Pharmacokinet 2004; 43: 1071–1087.

36.

Villani

, Floridia

, Pirillo

M.F.

Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.

Br J Clin Pharmacol 2006; 62: 309–315.

37.

Stek

A.M.

, Mirochnick

, Capparelli

Reduced lopinavir exposure during pregnancy.

AIDS 2006; 20: 1931–1939.

38.

Roustit

, Jlaiel

, Leclercq

, Stanke-Labesque

Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

Br J Clin Pharmacol 2008; 66: 179–195.

39.

Galli

, Puliti

, Chiappini

Is interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1?

Clin Infect Dis 2009; 48: 1310–1317.

40.

Schmitz

, Kleinkauf

, Klempa

, Ringe

, Varnholt

, Grosch-Worner

Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.

Pediatr Infect Dis J 2006; 25: 275–276.

41.

Karchava

, Pulver

, Smith

Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.

J Acquir Immune Defic Syndr 2006; 42: 614–619.